Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Enterprise Value (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Enterprise Value for 2 consecutive years, with -$10.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 92.82% to -$10.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$10.4 million, a 92.82% increase, with the full-year FY2024 number at -$126.9 million, changed N/A from a year prior.
  • Enterprise Value was -$10.4 million for Q3 2025 at Pyxis Oncology, up from -$88.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$10.4 million in Q3 2025 to a low of -$157.0 million in Q1 2024.